Research Library › Neuropeptides
Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH, also called LH-RH), the hypothalamic decapeptide pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2. Andrew Schally’s group sequenced it from pig hypothalami in 1971, and Roger Guillemin’s group did so from sheep in 1972. The two shared the 1977 Nobel Prize in Physiology or Medicine. Two human gonadorelin products were FDA-approved, Factrel (1982) and Lutrepulse (1989). As of 23 Oct 2026, both are listed as discontinued.
Key facts
| Type | Synthetic decapeptide (10 amino acids), identical in sequence to natural GnRH |
|---|---|
| Sequence | pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 |
| First described | 1971 (porcine, Schally group); 1972 (ovine, Guillemin group) |
| Recognition | 1977 Nobel Prize in Physiology or Medicine (Guillemin and Schally, shared with Rosalyn Yalow) |
| Natural target | GnRH receptors on gonadotrope cells of the anterior pituitary |
| FDA-approved human products | Factrel (gonadorelin HCl, NDA 018123, 1982) and Lutrepulse (gonadorelin acetate, NDA 019687, 1989), both discontinued |
| Regulatory status (Oct 2026) | No marketed FDA-approved human product; veterinary products approved; 503B Category 1 (under evaluation); WADA-prohibited in males |
Who discovered it
By the 1960s, researchers had predicted that the hypothalamus releases small peptides that control the pituitary gland. Two rival teams raced to isolate them: Andrew Schally’s, working mainly with pig hypothalami, and Roger Guillemin’s, working mainly with sheep hypothalami [5].
In 1971, H. Matsuo, Y. Baba, R.M. Nair, A. Arimura and Schally proposed the amino acid sequence of the porcine LH- and FSH-releasing hormone in Biochemical and Biophysical Research Communications [1]. A companion paper confirmed the structure by sequential degradation [2]. In 1972, Roger Burgus, Guillemin and colleagues reported the same ten-residue primary structure from sheep in PNAS [3]. In 1977 Guillemin and Schally shared half of the Nobel Prize in Physiology or Medicine “for their discoveries concerning the peptide hormone production of the brain”; Rosalyn Yalow received the other half [4].
What it targets
Gonadorelin has the same structure as natural GnRH: a decapeptide with an N-terminal pyroglutamate and a C-terminal glycinamide [2, 6]. Natural GnRH is released from the hypothalamus and acts on GnRH receptors on the gonadotrope cells of the anterior pituitary. These cells secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [5, 6]. The Schally team’s early finding that a single peptide controls the release of both hormones gave rise to the name LH-RH/FSH-RH [1]. In 1986, the human gene encoding the GnRH precursor was isolated and found to encode the same decapeptide in humans and rats [7].
Approved products and why they were made
Factrel, gonadorelin hydrochloride, was approved by the FDA on 30 Sep 1982 as a new molecular entity under NDA 018123 [8]. Ayerst Laboratories marketed it as a diagnostic agent, labeled for evaluating the functional capacity and response of the anterior pituitary gonadotropes [6]. Lutrepulse, gonadorelin acetate, was approved on 10 Oct 1989 under NDA 019687, as a product aimed at the fertility field [9, 10]. Drugs@FDA now lists Factrel (holder Hikma) and Lutrepulse (holder Ferring) as discontinued [8, 9].
Gonadorelin also has veterinary approvals. Cystorelin (gonadorelin diacetate tetrahydrate), for example, is FDA-approved for cattle under NADA 098-379 [11].
Research timeline
- 1971: Schally’s group proposes and confirms the porcine LH/FSH-releasing hormone sequence [1, 2].
- 1972: Guillemin’s group reports the ovine LRF primary structure [3].
- 1977: Nobel Prize to Guillemin and Schally (shared with Yalow) [4].
- 30 Sep 1982: FDA approves Factrel (gonadorelin HCl) [8].
- 10 Oct 1989: FDA approves Lutrepulse (gonadorelin acetate) [9].
- Oct 2021: University of Maryland M-CERSI summary report on gonadorelin acetate prepared for FDA’s 503B bulks evaluation [12].
Regulatory status as of October 2026
As of 23 Oct 2026, gonadorelin is an FDA-approved active ingredient, but both human products, Factrel and Lutrepulse, are listed as discontinued [8, 9]. Veterinary gonadorelin products remain approved [11].
Gonadorelin acetate is in Category 1 (“under evaluation”) of FDA’s 503B bulk drug substance nomination list (version updated 21 Mar 2025) [13]. It does not appear on the 503A nomination list (updated 14 May 2026) [14] or the Category 2 safety-risk list [15], and it was not on the 2026 agendas of FDA’s Pharmacy Compounding Advisory Committee [16]. The WADA 2026 Prohibited List names gonadotrophin-releasing hormone (gonadorelin) under S2 as prohibited in males [17].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Who discovered gonadorelin (GnRH)?
Andrew Schally’s group sequenced porcine GnRH in 1971, and Roger Guillemin’s group sequenced ovine GnRH in 1972. They shared the 1977 Nobel Prize in Physiology or Medicine for this line of work.
Is gonadorelin FDA approved?
Gonadorelin was approved in Factrel (1982) and Lutrepulse (1989), but Drugs@FDA lists both as discontinued as of 23 Oct 2026. Veterinary gonadorelin products for cattle remain FDA-approved.
What is gonadorelin's structure?
It is a decapeptide, pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, identical to natural hypothalamic GnRH.
Is gonadorelin the same as GnRH or LHRH?
Yes. Gonadorelin is the nonproprietary drug name for synthetic gonadotropin-releasing hormone, which is also known as luteinizing hormone-releasing hormone (LH-RH).
Sources
- Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun. 1971;43(6):1334-1339. Link
- Schally AV, Baba Y, Matsuo H. Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analyses. Biochem Biophys Res Commun. 1971;44:459-463. Link
- Burgus R, Butcher M, Amoss M, et al. Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor (LRF). Proc Natl Acad Sci U S A. 1972;69(1):278-282. Link
- NobelPrize.org. The Nobel Prize in Physiology or Medicine 1977 (summary). Link
- NobelPrize.org. The Nobel Prize in Physiology or Medicine 1977: press release. Link
- Factrel (gonadorelin hydrochloride) prescribing information, Ayerst Laboratories (via RxList). Link
- Adelman JP, Mason AJ, Hayflick JS, Seeburg PH. Isolation of the gene and hypothalamic cDNA for the common precursor of gonadotropin-releasing hormone and prolactin release-inhibiting factor in human and rat. Proc Natl Acad Sci U S A. 1986;83(1):179-183. doi:10.1073/pnas.83.1.179 Link
- U.S. FDA. Drugs@FDA: Factrel (gonadorelin hydrochloride), NDA 018123; approved 30 Sep 1982; marketing status Discontinued. Link
- U.S. FDA. Drugs@FDA: Lutrepulse Kit (gonadorelin acetate), NDA 019687; approved 10 Oct 1989; marketing status Discontinued. Link
- The Pink Sheet. Ortho Lutrepulse clears FDA; RW Johnson gets three late-1989 approvals. 1 Jan 1990. Link
- Cystorelin (gonadorelin diacetate tetrahydrate) label, Boehringer Ingelheim Animal Health USA; Approved by FDA under NADA 098-379 (via Drugs.com Vet). Link
- Gianturco SL, Pavlech LL, Storm KD, Yuen MV, Mattingly AN. Gonadorelin acetate: Summary Report. University of Maryland M-CERSI, October 2021. Link
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the FD&C Act (updated 21 Mar 2025). Link
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated 14 May 2026). Link
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 Apr 2026). Link
- Latham & Watkins. FDA on Peptides: A New Landscape for Compounders (2026), summarizing 91 Fed. Reg. 20465 (16 Apr 2026) and the PCAC meeting agendas. Link
- World Anti-Doping Agency. 2026 Prohibited List, as published in the Dutch Treaty Series (Tractatenblad 2026, 25), section S2. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
